Septic diaphragmatic dysfunction is prevented by Mn(III)porphyrin therapy and inducible nitric oxide synthase

Nicolás Nin1, Adriana Cassina, José Boggia

  • 1Department of Pathophysiology, Hospital de Clínicas, School of Medicine, Universidad de la República , Avenida Italia s/n, Piso 15, CP 11600 Montevideo, Uruguay.

Intensive Care Medicine
|September 7, 2004
PubMed
Abstract

Insights

A novel antioxidant, MnTE-2-PyP(5+), and aminoguanidine (AG) protected against sepsis-induced diaphragmatic and mitochondrial dysfunction by reducing nitric oxide overproduction and oxidative stress.

Area of Science:

  • Biomedical Science
  • Biochemistry
  • Pathophysiology

Background:

  • Sepsis leads to decreased diaphragmatic contractility and organ failure.
  • This is mediated by nitric oxide (NO)-derived species, targeting mitochondria and causing oxidative stress.

Purpose of the Study:

  • To evaluate the protective effects of a novel antioxidant, manganese(III) 5,10,15,20-tetrakis(N-ethylpyridinium-2-yl) porphyrin (MnTE-2-PyP(5+)), and an NO synthase inhibitor, aminoguanidine (AG).
  • To assess their impact on a rat model of sepsis-induced diaphragmatic and mitochondrial dysfunction.

Main Methods:

  • Sepsis induced via cecal ligation and perforation in rats.
  • Evaluated systemic hemodynamics, gas exchange, diaphragmatic function, and mitochondrial respiration.
  • Measured plasma and mitochondrial oxidative and nitrative stress markers.

Main Results:

  • Sepsis caused diaphragmatic dysfunction, reduced mitochondrial respiration, and increased oxidative and nitrative stress.
  • These sepsis-induced alterations were significantly ameliorated or prevented by MnTE-2-PyP(5+) or AG treatment.

Conclusions:

  • Overproduction of NO and its derivatives critically impairs mitochondria and diaphragmatic function in sepsis.
  • MnTE-2-PyP(5+) and AG show potential in ameliorating sepsis-induced dysfunction, possibly preventing organ failure.

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...